Article

PSA doubling time: Solid predictor of PCa survival

New Orleans--PSA doubling time (PSADT) appears to be a strong predictor of the probability of distant metastasis and prostate cancer-specific survival in men with biochemical relapse after radical prostatectomy, according to Mario A. Eisenberger, MD.

Related Videos
Mohamad Baker Berjaoui, MD, answers a question during a Zoom video interview
Medcast series
Elia Abou Charaweb, MD, answers a question during a video interview
Related Content
FDA greenlights pivotal trial of wearable bioelectronic device for OAB
December 12th 2024

FDA greenlights pivotal trial of wearable bioelectronic device for OAB

Hannah Clarke
The primary aims for the EVANESCE-II trial are to confirm the safety of the FemPulse System and to establish noninferiority to first-line tolterodine.
Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
Expanded Access Program to provide real-world data on cretostimogene grenadenorepvec
December 11th 2024

Expanded Access Program to provide real-world data on cretostimogene grenadenorepvec

Hannah Clarke
Cretostimogene grenadenorepvec is an investigational oncolytic immunotherapy for patients with BCG-unresponsive high-risk NMIBC.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
DNA molecules | Image Credit: © vitstudio - stock.adobe.com
December 10th 2024

Quiz: CUA guidelines on germline genetic testing in prostate cancer

Urology Times staff
Test your knowledge of his quiz the Canadian Urological Association's recommendations for germline genetic testing in prostate cancer management.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
December 9th 2024

High cystectomy-free survival seen with nadofaragene treatment in NMIBC

Benjamin P. Saylor
"Overall, the take-home message is that in patients with BCG-unresponsive non–muscle invasive bladder cancer, you can consider nadofaragene as an option among those that are available for treating these patients," said Vikram Narayan, MD.
© 2024 MJH Life Sciences

All rights reserved.